Nutri Pharmaceuticals Research Stock Net Income
| NRPR Stock | USD 0.02 0 20.00% |
As of the 13th of February 2026, Nutri Pharmaceuticals secures the Risk Adjusted Performance of 0.01, mean deviation of 3.26, and Standard Deviation of 12.86. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Nutri Pharmaceuticals, as well as the relationship between them. Please verify Nutri Pharmaceuticals risk adjusted performance and total risk alpha to decide if Nutri Pharmaceuticals Research is priced some-what accurately, providing market reflects its recent price of 0.016 per share. As Nutri Pharmaceuticals appears to be a penny stock we also strongly suggest to check its jensen alpha numbers.
Nutri Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Nutri Pharmaceuticals' valuation are provided below:Nutri Pharmaceuticals Research does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Nutri |
Nutri Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Nutri Pharmaceuticals' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Nutri Pharmaceuticals.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in Nutri Pharmaceuticals on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding Nutri Pharmaceuticals Research or generate 0.0% return on investment in Nutri Pharmaceuticals over 90 days. Nutri Pharmaceuticals Research, Inc. engages in the manufacture and sale of health, beauty, and food ingredients, as wel... More
Nutri Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Nutri Pharmaceuticals' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Nutri Pharmaceuticals Research upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 129.28 | |||
| Value At Risk | (17.36) |
Nutri Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nutri Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Nutri Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Nutri Pharmaceuticals historical prices to predict the future Nutri Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.01 | |||
| Jensen Alpha | (0.07) | |||
| Total Risk Alpha | (1.12) | |||
| Treynor Ratio | (0.0007) |
Nutri Pharmaceuticals February 13, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.01 | |||
| Market Risk Adjusted Performance | 0.0093 | |||
| Mean Deviation | 3.26 | |||
| Coefficient Of Variation | 138215.81 | |||
| Standard Deviation | 12.86 | |||
| Variance | 165.43 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.07) | |||
| Total Risk Alpha | (1.12) | |||
| Treynor Ratio | (0.0007) | |||
| Maximum Drawdown | 129.28 | |||
| Value At Risk | (17.36) | |||
| Skewness | 3.05 | |||
| Kurtosis | 27.1 |
Nutri Pharmaceuticals Backtested Returns
Currently, Nutri Pharmaceuticals Research is out of control. Nutri Pharmaceuticals has Sharpe Ratio of close to zero, which conveys that the firm had a close to zero % return per unit of risk over the last 3 months. We have found nineteen technical indicators for Nutri Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please verify Nutri Pharmaceuticals' Risk Adjusted Performance of 0.01, standard deviation of 12.86, and Mean Deviation of 3.26 to check out if the risk estimate we provide is consistent with the expected return of 0.0101%. The company secures a Beta (Market Risk) of 0.96, which conveys possible diversification benefits within a given portfolio. Nutri Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Nutri Pharmaceuticals is expected to follow. Nutri Pharmaceuticals right now secures a risk of 13.39%. Please verify Nutri Pharmaceuticals Research total risk alpha and day typical price , to decide if Nutri Pharmaceuticals Research will be following its current price movements.
Auto-correlation | -0.62 |
Very good reverse predictability
Nutri Pharmaceuticals Research has very good reverse predictability. Overlapping area represents the amount of predictability between Nutri Pharmaceuticals time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Nutri Pharmaceuticals price movement. The serial correlation of -0.62 indicates that roughly 62.0% of current Nutri Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.62 | |
| Spearman Rank Test | -0.64 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Nutri Pharmaceuticals Research reported net income of (467,590). This is 100.14% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is 100.08% higher than that of the company.
Nutri Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nutri Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Nutri Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Nutri Pharmaceuticals by comparing valuation metrics of similar companies.Nutri Pharmaceuticals is currently under evaluation in net income category among its peers.
Nutri Fundamentals
| Profit Margin | (0.39) % | |||
| Operating Margin | (0.38) % | |||
| Current Valuation | 67.46 K | |||
| Shares Outstanding | 938.62 K | |||
| Price To Earning | 0.07 X | |||
| Price To Sales | 0.03 X | |||
| Revenue | 1.21 M | |||
| Gross Profit | 18.95 K | |||
| EBITDA | (423.34 K) | |||
| Net Income | (467.59 K) | |||
| Cash And Equivalents | 90.07 K | |||
| Cash Per Share | 0.09 X | |||
| Total Debt | 125.86 K | |||
| Debt To Equity | 0.53 % | |||
| Current Ratio | 0.72 X | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | 22.68 K | |||
| Earnings Per Share | (0.65) X | |||
| Beta | -1.87 | |||
| Market Capitalization | 30.22 K |
About Nutri Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nutri Pharmaceuticals Research's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nutri Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nutri Pharmaceuticals Research based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Nutri Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nutri Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nutri Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Nutri Pink Sheet
| 0.45 | ABEV | Ambev SA ADR Aggressive Push | PairCorr |
| 0.38 | HLNCF | Haleon plc | PairCorr |
| 0.35 | HLN | Haleon plc Aggressive Push | PairCorr |
The ability to find closely correlated positions to Nutri Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nutri Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nutri Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nutri Pharmaceuticals Research to buy it.
The correlation of Nutri Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nutri Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nutri Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nutri Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Nutri Pink Sheet Analysis
When running Nutri Pharmaceuticals' price analysis, check to measure Nutri Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nutri Pharmaceuticals is operating at the current time. Most of Nutri Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Nutri Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nutri Pharmaceuticals' price. Additionally, you may evaluate how the addition of Nutri Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.